• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Anika Reports Second Quarter 2025 Financial Results

    7/30/25 7:05:25 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email

    Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025

    Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025

    Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch

    BEDFORD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the second quarter ended June 30, 2025.

    Second Quarter 2025 Results

    Anika reported second quarter revenue from continuing operations of $28.2 million, an 8% decrease compared to the same period in 2024. Commercial Channel revenue was flat year-over-year, while OEM Channel revenue, which includes U.S. OA Pain Management, was down 13% in line with expectations. The decline was driven by lower pricing for Monovisc® and Orthovisc®, sold by our commercial partner, J&J MedTech.

    Cheryl Blanchard, President and CEO of Anika Therapeutics, commented: "We continue to see strength in our Commercial Channel with Regenerative Solutions revenue increasing 41% in the quarter driven by Integrity's outperformance and continued strong International Hyalofast growth. International OA Pain Management revenue was modestly lower in the quarter; however, remained flat through the first half of 2025, reflecting increased order demand in Q2 2024 and the temporary impact of our recent production yield issues. Importantly, there was no impact on delivery of products to patients as a result of these temporary issues and in June we returned to full production. After a challenging first quarter, pricing for US OA Pain Management products rebounded in the second quarter and is expected to represent the high point for the year. As previously communicated, we anticipate a more pronounced decline in pricing during the second half of 2025, with normalization expected as we enter 2026 as end-user pricing for Monovisc and Orthovisc converge more in line with market competitors. From an expense perspective, we continue to make excellent progress on our cost-saving measures, resulting in a 17% decline in operating expenses for the quarter."

    Dr. Blanchard continued: "Earlier today we announced topline results of our U.S. Hyalofast clinical trial. While we are disappointed that the study did not meet its pre-specified co-primary endpoints, we are encouraged by the consistent improvements Hyalofast demonstrated over microfracture, including statistically significant improvements in pre-defined secondary endpoints and other measures. These results, combined with clinical data from over 15-years of successful real-world use in Europe, reinforce our confidence in Hyalofast's potential to address a critical unmet need in cartilage repair. We remain committed to advancing this breakthrough therapy and look forward to submitting the final PMA module to the FDA later this year, as planned."

    Strong Integrity Commercial Performance and Portfolio Expansion

    Integrity procedures grew for the fifth consecutive quarter and are on track to significantly outpace the overall growth of the U.S. soft tissue augmentation market. During the quarter, Anika received FDA 510(k) clearance to expand the Integrity platform with new shapes and sizes. The newly cleared 40x60mm and 25x60mm Integrity implants are expected to be available for a limited release in the U.S. by year-end, initially targeting Achilles repair in the foot and other larger tendon applications in the knee and hip. These additions are anticipated to drive increased adoption and support continued commercial momentum into 2026.

    International OA Pain Management in Line with Previous Quarters

    Anika's International Sales organization continues to deliver strong results, driven by increased market share and successful entry into new markets. Second quarter revenue grew 5% sequentially, though declined 10% year-over-year, primarily due to order timing in 2024 and the temporary impact of recent production-related yield issues. Anika expects the effects of the production yield issues to be fully resolved by the end of the third quarter and remains confident in its ability to achieve full-year 2025 International OA Pain Management growth projections.

    Hyalofast Clinical Study Results and Program Update

    Earlier today, Anika announced topline results from its U.S. Phase III FastTRACK clinical trial evaluating Hyalofast, a single-stage, resorbable, hyaluronic acid scaffold for cartilage repair. Although the study did not achieve its pre-specified co-primary endpoints for pain and function, Hyalofast demonstrated consistent improvements over microfracture, including statistically significant improvements in secondary endpoints and other measures such as KOOS Sports and Recreation Function, Quality of Life, and Total KOOS. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. Based on the strength and consistency of the overall data including clinical data from independent clinical studies performed outside the U.S over the past 15 years, Anika intends to submit the final PMA module in the second half of 2025 as previously disclosed. Please refer to the press release issued this morning for additional details.

    Progress on Final Steps to Cingal NDA Filing

    During the quarter, Anika advanced key activities toward filing the NDA for Cingal, its novel, next-generation, non-opioid, single-injection OA Pain Management product, consisting of its proprietary cross-linked hyaluronic acid combined with a fast-acting steroid. These activities included progress on the ongoing toxicity studies and preparations for the bioequivalence study planned to start later this year. The completion of these two studies will mark a significant milestone and remain the final requirements for NDA submission in the U.S.

    Operations Update

    Anika has resolved the production yield issues it faced earlier this year. Throughout this period, the company maintained uninterrupted product supply to ensure no impact on patient treatments. The current focus is on replenishing distributor inventory levels through the third quarter. With improvements now in place, Anika expects increased throughput of Monovisc and Cingal, and is enhancing plant capacity to support future growth.

    Update on Previously Announced Divestitures

    Anika has now successfully completed all material transitional services with respect to the sale of both Arthrosurface and Parcus Medical.

    Second Quarter 2025 Continuing Operations Financial Summary (compared to the second quarter of 2024)

    • Revenue $28.2 million, decreased 8%
      • OEM Channel revenue $16.3 million, decreased 13%
      • Commercial Channel revenue $11.9 million, flat
    • Gross margin 51% (including $3.0 million of inventory obsolescence and scrap charges in the quarter related to lower production yields)
    • Operating expenses $18.5 million, decreased 17%
    • Loss from continuing operations ($4.6) million, ($0.33) per share
    • Adjusted net loss from continuing operations1 ($1.7) million, ($0.13) per share
    • Adjusted EBITDA1 ($0.2) million
    • Cash used in operating activities for total Company $0.2 million
    • Cash balance $53.2 million

    1 See description of non-GAAP financial information contained in this release.

    Maintaining Fiscal 2025 Guidance

    Anika maintains 2025 revenue ranges by channel as follows:

    • Commercial Channel, unchanged, of $47 to $49.5 million, up 12% to 18% year-over-year
    • OEM Channel, unchanged, of $62 to $65 million, down 16% to 20% year-over-year

    Anika maintains Adjusted EBITDA of -3% to 3%

    Updating 2026-2027 Long Term Revenue Guidance for Potential Delay of Hyalofast Launch

    Commercial Channel expected to grow +10% to +20% in 2026 and 2027 as compared to the previous guidance of +20% to +30% in 2026 and 2027, based on the anticipated launch of Hyalofast now in 2027. The company assumes $3 million of initial sales in 2027 for Hyalofast.

    Conference Call and Webcast Information

    Anika's management will hold a conference call and webcast to discuss its financial results and business highlights today, Wednesday, July 30, 2025, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 48251. A live audio webcast will be available in the Investor Relations section of Anika's website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika's website approximately two hours after the completion of the event.

    About Anika

    Anika Therapeutics, Inc. (NASDAQ:ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

    ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

    Non-GAAP Financial Information1

    Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with GAAP. Furthermore, the Company's definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, Anika strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company's operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

    Adjusted EBITDA

    Adjusted EBITDA is defined by the Company as GAAP net income (loss) from continuing operations excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, and shareholder activism costs.

    Adjusted Net Income (Loss) from Continuing Operations and Adjusted EPS from Continuing Operations

    Adjusted net income (loss) is defined by the Company as GAAP net income from continuing operations, on a tax effected basis, excluding stock-based compensation. Adjusted diluted EPS from continuing operations is defined by the Company as GAAP diluted EPS from continuing operations excluding stock-based compensation.

    A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

    Forward-Looking Statements

    This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including statements about the planned launch of new shape and sizes and the potential growth of the Integrity Implant System, statements in Dr. Blanchard's quote about anticipated pricing of Monovisc and Orthovisc in the U.S., statements about the timing and potential success of the clinical and regulatory pathway and launch of Hyalofast in the U.S., statements about the anticipated regulatory pathway for the NDA filing for Cingal, statements about the final resolution of the impacts of the production yield issues experienced earlier in the year, and in the section titled "Maintaining Fiscal 2025 Guidance" and "Updating 2026-2027 Long Term Revenue Guidance for Potential Delay of Hyalofast Launch". These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support, or to timely file domestic and international pre-market approval applications, 510(k) applications, or new drug applications, including the third PMA module for Hyalofast, (iii) that the FDA or other regulatory bodies may not approve or clear the Company's applications, including the Hyalofast PMA because of the failure to achieve the pre-defined primary endpoints or because the FDA may determine that achievement of secondary endpoints and/or post hoc data analyses are not sufficient to support approval; (iii) that such approvals or clearances will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

    For Investor Inquiries:

    Anika Therapeutics, Inc.

    Matt Hall, 781-457-9554

    Director, Corporate Development and Investor Relations

    [email protected]

             
    Anika Therapeutics, Inc. and Subsidiaries
    Consolidated Statements of Operations
    (in thousands, except per share data)
    (unaudited)
             
      For the Three Months Ended June 30, For the Six Months Ended June 30,
       2025   2024   2025   2024 
    Revenue $28,219  $30,724  $54,387  $59,746 
    Cost of Revenue  13,856   10,235   25,343   20,282 
    Gross Profit  14,363   20,489   29,044   39,464 
             
    Operating expenses:        
    Research and development  6,313   6,682   12,372   13,091 
    Selling, general and administrative  12,230   15,617   25,136   30,688 
    Total operating expenses  18,543   22,299   37,508   43,779 
    Loss from operations  (4,180)  (1,810)  (8,464)  (4,315)
    Interest and other income (expense), net  214   595   629   1,187 
    Loss before income taxes  (3,966)  (1,215)  (7,835)  (3,128)
    Provision for income taxes  681   1,326   770   1,369 
    Loss from continuing operations  (4,647)  (2,541)  (8,605)  (4,497)
    Loss from discontinued operations, net of tax  677   2,453   (238)  (105)
    Net loss $(3,970) $(88) $(8,843) $(4,602)
             
    Net loss per share:        
    Basic        
    Continuing Operations $(0.33) $(0.17) $(0.60) $(0.30)
    Discontinued Operations $0.05  $0.16  $(0.02) $(0.01)
      $(0.28) $(0.01) $(0.62) $(0.31)
             
    Diluted        
    Continuing Operations $(0.33) $(0.17) $(0.60) $(0.30)
    Discontinued Operations $0.05  $0.17  $(0.02) $(0.01)
      $(0.28) $(0.00) $(0.62) $(0.31)
             
    Weighted average common shares outstanding:        
    Basic  14,364   14,839   14,331   14,769 
    Diluted  14,517   14,856   14,331   14,769 



        
    Anika Therapeutics, Inc. and Subsidiaries
    Consolidated Balance Sheets
    (in thousands, except per share data)
    (unaudited)
        
     June 30, December 31,
    ASSETS 2025   2024 
    Current assets:   
    Cash and cash equivalents$53,167  $55,629 
    Accounts receivable, net 23,955   23,594 
    Inventories, net 16,922   23,809 
    Prepaid expenses and other current assets 5,273   5,494 
    Current assets held for sale -   5,126 
    Total current assets 99,317   113,652 
    Property and equipment, net 41,083   38,994 
    Right-of-use assets 24,722   25,685 
    Other long-term assets 5,550   5,656 
    Notes receivable 6,039   5,935 
    Deferred tax assets 1,254   1,177 
    Intangible assets, net 1,661   2,490 
    Goodwill 8,056   7,125 
    Non-current assets held for sale -   2,026 
    Total assets$187,682  $202,740 
        
    LIABILITIES AND STOCKHOLDERS' EQUITY   
    Current liabilities:   
    Accounts payable$4,771  $5,617 
    Accrued expenses and other current liabilities 11,310   13,567 
    Current liabilities held for sale -   4,122 
    Total current liabilities 16,081   23,306 
    Other long-term liabilities 756   772 
    Lease liabilities 23,173   24,014 
    Non-current liabilities held for sale -   659 
        
    Stockholders' equity:   
    Common stock, $0.01 par value 144   144 
    Additional paid-in-capital 89,459   88,961 
    Accumulated other comprehensive loss (4,755)  (6,783)
    Retained earnings 62,824   71,667 
    Total stockholders' equity 147,672   153,989 
    Total liabilities and stockholders' equity$187,682  $202,740 



          
    Anika Therapeutics, Inc. and Subsidiaries

    Reconciliation of GAAP Net Loss from Continued Operations to Adjusted EBITDA

    (in thousands)
    (unaudited)
             
      For the Three Months Ended June 30, For the Six Months Ended June 30,
       2025   2024   2025   2024 
    Net loss from continuing operations $(4,647) $(2,541) $(8,605) $(4,497)
    Interest and other (income) expense, net  (214)  (595)  (629)  (1,187)
    Provision for income taxes  681   1,326   770   1,369 
    Depreciation and amortization  1,444   1,376   2,859   2,750 
    Stock-based compensation  2,548   3,535   5,543   6,789 
    Costs of shareholder activism  -   1,584   -   2,185 
    Adjusted EBITDA $(188) $4,685  $(62) $7,409 
             
             
             
    Anika Therapeutics, Inc. and Subsidiaries
    Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
    (in thousands)
    (unaudited)
             
      For the Three Months Ended June 30, For the Six Months Ended June 30,
       2025   2024   2025   2024 
    Loss from continuing operations $(4,647) $(2,541) $(8,605) $(4,497)
    Share-based compensation, tax effected  2,986   2,176   6,088   7,398 
    Costs of shareholder activism, tax effected  -   975   -   2,381 
    Adjusted net (loss) income from continuing operations $(1,661) $610   (2,517) $5,282 
             
    Anika Therapeutics, Inc. and Subsidiaries
    Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Operations Per Share
    (in thousands, except per share data)
    (unaudited)
             
      For the Three Months Ended June 30, For the Six Months Ended June 30,
       2025   2024   2025   2024 
    Diluted loss from continuing operations per share $(0.33) $(0.17) $(0.60) $(0.31)
    Share-based compensation, tax effected  0.20   0.14   0.43   0.51 
    Costs of shareholder activism, tax effected  -   0.07   -   0.16 
    Adjusted diluted net (loss) income per share $(0.13) $0.04  $(0.17) $0.36 





                    
    Anika Therapeutics, Inc. and Subsidiaries
    Revenue by Product Family
    (in thousands, except percentages)
    (unaudited)
                      
     For the Three Months Ended June 30, For the Six Months Ended June 30,

      2025   2024  $ change % change  2025   2024  $ change   % change 
    OEM Channel$16,340  $18,887  $(2,547)  -13% $31,249  $38,337  $(7,088)  -18%
    Commercial Channel 11,879   11,837   42   0%  23,138   21,409   1,729   8%
     Revenue$28,219  $30,724  $(2,505)  -8% $54,387  $59,746  $(5,359)  -9%
                      


    Primary Logo

    Get the next $ANIK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Vogt Susan L N was granted 14,164 shares, increasing direct ownership by 39% to 50,213 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/24/25 5:14:37 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Director Richard Stephen was granted 14,164 shares, increasing direct ownership by 42% to 47,871 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/24/25 5:13:40 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Director Larsen Glenn R. was granted 14,164 shares, increasing direct ownership by 39% to 50,258 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/24/25 5:13:04 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anika Reports Second Quarter 2025 Financial Results

      Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch BEDFORD, Mass., July

      7/30/25 7:05:25 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update

      Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements over microfracture in pre-defined secondary endpoints and other measures that align with prior FDA approvals for cartilage repair products Hyalofast has been used to treat over 35,000 patients in more than 35 countries outside the U.S. since 2009; data from independent studies performed outside the U.S. will be filed with FDA submission Based on the totality of the data, Anika plans to file the final PMA module in H2 2025

      7/30/25 7:00:41 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025

      BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 48251. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.ani

      7/16/25 4:01:18 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Anika Therapeutics Inc.

      10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

      7/30/25 4:12:28 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

      7/30/25 7:21:00 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

      7/30/25 7:15:28 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

      B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Barrington Research reiterated coverage on Anika Therapeutics with a new price target

      Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

      11/1/24 10:25:08 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics upgraded by Barrington Research with a new price target

      Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

      8/14/23 9:16:10 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    See more
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care
    • Anika Enters into Cooperation Agreement with Caligan Partners

      Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

      5/28/24 4:05:00 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Announces CFO Transition

      BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve

      5/8/24 4:08:54 PM ET
      $ANIK
      $VSEC
      Medical/Dental Instruments
      Health Care
      Military/Government/Technical
      Consumer Discretionary

    $ANIK
    Financials

    Live finance-specific insights

    See more
    • Anika Reports Second Quarter 2025 Financial Results

      Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch BEDFORD, Mass., July

      7/30/25 7:05:25 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025

      BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 48251. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.ani

      7/16/25 4:01:18 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports First Quarter 2025 Financial Results

      First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter reven

      5/9/25 7:05:26 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

      SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

      11/8/24 2:17:24 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

      SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

      5/30/24 4:31:25 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

      SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

      3/6/24 7:30:09 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care